Xifaxanta: antibacterial for travellers' diarrhoea

Xifaxanta (rifaximin) is a non-absorbed rifamycin which is licensed for the treatment of non-invasive travellers' diarrhoea.

Xifaxanta is not indicated if diarrhoea is associated with fever, blood/leucocytes present in stools or if ≥8 unformed stools in 24 hours
Xifaxanta is not indicated if diarrhoea is associated with fever, blood/leucocytes present in stools or if ≥8 unformed stools in 24 hours

PHARMACOLOGY

Rifaximin is a rifamycin antibacterial that irreversibly binds to the beta subunit of RNA-polymerase, inhibiting the synthesis of bacterial RNA. Less than 1% of the dose is absorbed from the GI tract, resulting in negligible plasma levels (<10 nanogram/ml).1

CLINICAL STUDIES

The efficacy of rifaximin for treating non-invasive travellers’ diarrhoea was established in 2 randomised, double-blind studies: rifaximin was compared with placebo in the first study2 and  with ciprofloxacin or placebo in the second.3 In both studies, time to last unformed stool (TLUS) was used as the primary efficacy endpoint.

In the first study (n=380), rifaximin 200mg 3 times daily for 3 days was compared with placebo. Median TLUS was significantly shorter in the treatment arm than in the placebo arm (32.5 hours vs 60.0 hours; p=0.0001).2

In the second study (n=399), the median TLUS for patients treated with rifaximin 200mg 3 times daily for 3 days was less than half that of the placebo group (32.0 hours vs 65.5 hours; p=0.001). Additionally, rifaximin demonstrated non-inferiority to ciprofloxacin 500mg twice daily for 3 days (28.8 hours; p=0.35).3

Owing to the poor systemic absorption of rifaximin, adverse effects are restricted to headache and gastrointestinal disturbances including abdominal pain, nausea and diarrhoea.  However, in both studies the adverse event profile in the rifaximin group did not significantly differ from that observed in the placebo groups.1-3

REFERENCES

  1. Xifaxanta Summary of Product Characteristics, June 2011.
  2. Steffen et al. Am J Gastroenterol 2003; 98: 1073–8.
  3. Taylor DN et al. Am J Trop Med Hyg 2006; 74: 1060–6.

View Xifaxanta drug record

Further information: Norgine Pharmaceuticals Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases